Days after handing to the FDA the first parts of a rolling new drug application for satraplatin, GPC Biotech AG found an ex-U.S. marketing partner for the oral platinum-based compound, which is in development to treat hormone-refractory prostate cancer. (BioWorld Today)
A missed primary endpoint in a pivotal study of its lung cancer brain metastases drug, Xcytrin, sent Pharmacyclics Inc.'s stock plunging more than 64 percent Monday. (BioWorld Today)
Partnering a promising preclinical pain product, Vertex Pharmaceuticals Inc. granted GlaxoSmithKline plc worldwide development and commercialization rights in a deal worth up to $405 million plus royalties. (BioWorld Today)
